Cargando…

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies

Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options have existed for this subtype of breast cancer, with cytotoxic chemotherapy playing a predominant role. This article aims...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacDonald, Isaiah, Nixon, Nancy A., Khan, Omar F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317013/ https://www.ncbi.nlm.nih.gov/pubmed/35877238 http://dx.doi.org/10.3390/curroncol29070378

Ejemplares similares

RNA nanoparticles for targeted therapies of triple-negative breast cancers
por: Danai, Leyla, et al.
Publicado: (2023)

Complete Resolution of Paraneoplastic Membranous Nephropathy Following Curative Therapy of Triple-Negative Breast Cancer
por: Khan, Muhammad B, et al.
Publicado: (2021)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
por: Stefanski, Casey D., et al.
Publicado: (2022)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Triple-negative breast cancer therapy: Current and future perspectives (Review)
por: Won, Kwang-Ai, et al.
Publicado: (2020)

A review of current progress in triple-negative breast cancer therapy
por: Shen, Meiying, et al.
Publicado: (2020)

Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2022)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Super-enhanced MARCO variant drives triple-negative breast cancer progression
por: Lin, Weei-Chin, et al.
Publicado: (2022)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer
por: Dias, Cristina J., et al.
Publicado: (2021)

RARRES2’s impact on lipid metabolism in triple-negative breast cancer: a pathway to brain metastasis
por: Shubhra, Quazi T. H.
Publicado: (2023)

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer
por: Mekky, Radwa Y., et al.
Publicado: (2023)

An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancers
por: Rajarajan, Savitha, et al.
Publicado: (2023)

Comment to “Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis”
por: Altundag, Kadri
Publicado: (2016)

Role of eIF4A1 in triple‐negative breast cancer stem‐like cell‐mediated drug resistance
por: Raman, Dayanidhi, et al.
Publicado: (2020)

Peri-operative hemodynamic therapy: only large clinical trials can resolve our uncertainty
por: MacDonald, Neil, et al.
Publicado: (2011)

Current approaches in treatment of triple-negative breast cancer
por: Wahba, Hanan Ahmed, et al.
Publicado: (2015)

Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Słodkowski, Maciej, et al.
Publicado: (2023)

Comment on “comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian women” by Saleh et al.
por: Brody, James P.
Publicado: (2021)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Triple-negative breast cancer: A run-through of features, classification and current therapies
por: Manjunath, Meghana, et al.
Publicado: (2021)

Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions
por: Morrison, Laura, et al.
Publicado: (2023)

A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen)
por: Ritter, Deborah I., et al.
Publicado: (2019)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma
por: Zane, Kylie E, et al.
Publicado: (2022)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

Radical segmentectomy as a potential alternative surgical treatment with curative intent in early-stage non-small cell lung cancer
por: Koike, Terumoto, et al.
Publicado: (2020)

Triple-negative breast cancer and radiation therapy
por: de Faria Bessa, Jordana, et al.
Publicado: (2022)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer
por: Haque, Sakib, et al.
Publicado: (2021)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

A Reflection on a Data Curation Journey
por: Lötter, Lucia, et al.
Publicado: (2015)

Revision of RUNX1 variant curation rules
por: Feurstein, Simone, et al.
Publicado: (2022)

The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
por: Temian, Daiana Cosmina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r1uvhbos8ggatv58j2ea4efvlf